Compare GABC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | NVCR |
|---|---|---|
| Founded | 1910 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1995 | 2015 |
| Metric | GABC | NVCR |
|---|---|---|
| Price | $49.59 | $17.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $47.67 | $28.08 |
| AVG Volume (30 Days) | 133.2K | ★ 1.2M |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | 8.13 | ★ 21.79 |
| EPS | ★ 1.90 | N/A |
| Revenue | $487,401,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $16.78 | $7.72 |
| Revenue Next Year | $3.98 | $6.74 |
| P/E Ratio | $26.12 | ★ N/A |
| Revenue Growth | ★ 37.80 | 8.28 |
| 52 Week Low | $37.19 | $9.82 |
| 52 Week High | $52.23 | $21.45 |
| Indicator | GABC | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 52.55 |
| Support Level | $49.23 | $14.84 |
| Resistance Level | $51.97 | $18.37 |
| Average True Range (ATR) | 0.92 | 0.74 |
| MACD | -0.26 | 0.01 |
| Stochastic Oscillator | 40.89 | 56.48 |
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.